published on 09/16/2026 at 18:01

VERAXA Biotech (NASDAQ: VRXA) Building a New Approach to Precision Cancer Therapy

Austin, Texas, September 16th, 2026, FinanceWire

VERAXA is developing antibody-based cancer therapies aimed at improving the therapeutic window of existing treatment modalities.
Its proprietary BiTAC platform uses two complementary molecules that are designed to activate cytotoxic activity only when both recognize targets on the same tumor cell.
The company is applying the BiTAC concept to both antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), with an emphasis on solid tumors.
With ADCs and bispecific antibodies attracting substantial investment, VERAXA is operating in oncology markets where technological differentiation can have significant strategic value.

VERAXA Biotech (NASDAQ: VRXA) is developing a new generation of antibody-based cancer therapies at a time when oncology research is increasingly focused on a difficult question: how can powerful treatments be made more selective without sacrificing their ability to kill cancer cells? The wiss biotechnology company is approaching that problem through a portfolio of antibody-drug conjugates (“ADCs”), T-cell engagers (“TCEs”) and engineered antibody formats. At the center of the strategy is its proprietary BiTAC, or Bi-targeted Tumor-Associated Cytotoxicity, concept.

The objective is not simply to produce another antibody with a new target. VERAXA is attempting to change the…